Alcohol May Reduce Risk of Thyroid Cancer

By CancerConsultants.com
 

Researchers affiliated with the NIH-AARP Diet and Health Study have reported that alcohol intake may reduce the risk of thyroid cancer. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.[1]

The causes of thyroid cancer are generally obscure, although radiation exposure is a known cause. There is also an increased incidence in certain families.

Alcohol consumption is associated with an increased risk of several cancers, including head and neck, esophageal, breast, stomach, colon, liver, pancreas, prostate, and lung. However, risk for a few cancers, such as bladder cancer, do not appear to be increased by drinking alcohol.

Researchers involved in the current study sought to determine if there was any relationship between alcohol consumption and thyroid cancer. The NIH-ASRP Diet and Health Study includes almost 500,000 persons. Thyroid cancer was diagnosed in 170 men and 200 women. Persons who consumed two or more alcoholic drinks per day had a 43% increase in the risk of developing thyroid cancer.

Comments: Thyroid cancer is possibly the only cancer associated with a lower incidence in drinkers. There are suggestive data for a decreased risk of bladder cancer among drinkers, which was more pronounced with beer drinking than for spirits or wine.[2] A purported mechanism for alcohol protection from bladder cancer was “flushing” from increased urination. The mechanism for alcohol protecting from thyroid cancer is unknown.

References:

[1] Meinhold CL, Park Y, Stolzenberg-Soloman et al. Alcohol intake and risk of thyroid cancer in the NIH-AARP diet and health study. British Journal of Cancer. 2009;101:1630-1634.

[2] Jiang X, Castelao JE, Groshen S, et al. Alcohol consumption and risk of bladder cancer in Los Angeles County. International Journal of Cancer. 2007;121:839-845. 

Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health